Search

Your search keyword '"Negrier, S."' showing total 423 results
Start Over Author "Negrier, S."
423 results on '"Negrier, S."'

3. 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial

Author

Gruenwald, V., primary, McKay, R.R., additional, Buchler, T., additional, Eto, M., additional, Park, S.H., additional, Takagi, T., additional, Zanetta, S., additional, Keizman, D., additional, Rodriguez, C. Suarez, additional, Negrier, S., additional, Lee, J-L., additional, Santini, D., additional, Bedke, J., additional, Staehler, M., additional, Kollmannsberger, C.K., additional, Choueiri, T.K., additional, Motzer, R.J., additional, Burgents, J., additional, Okpara, C.E., additional, and Powles, T.B., additional

Published
2023
Full Text
View/download PDF

5. 1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era

Author

Thouvenin, J., primary, Alhalabi, O., additional, Carlo, M., additional, Carril Ajuria, L., additional, Bakouny, Z., additional, Martinez Chanza, N., additional, Negrier, S., additional, Campedel, L., additional, Bilen, M.A., additional, Borchiellini, D., additional, Chahoud, J., additional, Vano, Y-A., additional, Lodi, M., additional, Barthelemy, P., additional, Viswanathan, S.R., additional, Msaouel, P., additional, Choueiri, T.K., additional, Albiges, L., additional, Tannir, N., additional, and Malouf, G., additional

Published
2022
Full Text
View/download PDF

7. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Author

Colomba, E., primary, Carril Ajuria, L., additional, Dalban, C., additional, Derosa, L., additional, Alves Costa Silva, C., additional, Rassy, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis Mescam, G., additional, Oudard, S., additional, Laguerre, B., additional, Barthelemy, P., additional, Gross Goupil, M., additional, Geoffrois, L., additional, Thiery-Vuillemin, A., additional, Joly Lobbedez, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2022
Full Text
View/download PDF

9. Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Author

Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, and Chen C

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon, France; 4Pfizer Global Outcomes Research, New York, NY, USA Background: The debate surrounding the acceptance of progression-free survival (PFS) as an intermediate endpoint to overall survival (OS) has grown in recent years, due to the challenges in demonstrating an OS benefit within clinical trials today. PFS is generally a good predictor of OS for cases where survival post-progression (SPP) is short, and less so when SPP is long. SPP depends on multiple factors, including residual effect from experimental treatment and effect from crossover or other subsequent therapies, posing unique challenges into the translation of PFS benefit into OS. Methods: The objective of this analysis was to conduct simulations investigating how increasing SPP impacts PFS translation to OS, utilizing data from the AXIS (axitinib versus sorafenib in advanced metastatic renal cell carcinoma) trial. The underlying assumption was a treatment benefit in PFS (the PFS distribution parameters were chosen to be equal to median PFS in the AXIS trial) but no treatment effect on SPP, implying that PFS improvement is directly reflected in OS improvement. Results: The probability of a statistically significant difference between arms for OS decreased from 54.7% to 6.1% when median SPP was increased from one to 20 months. The probability of the hazard ratio of OS being ≥0.9 was similarly increased from 24.3% to 72.6%, even though the hazard ratio for PFS was 0.69. Conclusion: The present study shows that when simulated SPP is added to trial PFS data, the existing PFS benefit is diluted. Knowing that the AXIS treatment arms are well balanced with respect to post-trial treatments, we conclude that the PFS to OS benefit translation is primarily obscured by random variability largely unrelated to the true outcomes. The implications for drug development are not insignificant, as there would be a need to include more patients in studies or utilize a longer follow-up time to overcome the SPP variability issue. Keywords: overall survival, progression-free survival, endpoints, clinical trials, oncology, retrospective

Published
2014

15. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

Author

Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T. K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P. J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T., Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, and Wolter, Pascal

Published
2015
Full Text
View/download PDF

22. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

Author

Alves Costa Silva, C., primary, Derosa, L., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

23. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

24. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

Author

Grünwald, V., McKay, R.R., Buchler, T., Masatoshi, E., Park, S.H., Takagi, T., Zanetta, S., Keizman, D., Suárez, C., Négrier, S., Lee, J.L., Santini, D., Bedke, J., Staehler, M., Kollmannsberger, C., Choueiri, T., Motzer, R., Burgents, J., Okpara, C., and Powles, T.

Published
2023
Full Text
View/download PDF

26. An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Author

Ahrens, M., Escudier, B., Haanen, J. B. A. G., Boleti, E., Goupil, Gross M., Grimm, M. O., Negrier, S., Barthelemy, P., Gwenaelle Gravis, Ivany, P., Bedke, J., Castellano, D., Panic, A., Mellado, B., Maroto, J. P., Roten, S., Zschaebitz, S., Deckbar, D., Hartmann, A., and Bergmann, L.

Subjects
Medizin
Published
2021

28. 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

Author

Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., and Albiges, L.

Published
2023
Full Text
View/download PDF

31. GETUG collaborative group. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma : Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Author

Negrier, S, Rioux-Leclercq, N, Ferlay, C, Gross-Goupil, M, Gravis, G, Geoffrois, L, Chevreau, C, Boyle, H, Rolland, F, Blanc, E, Ravaud, A, Dermeche, S, Flechon, A, Albiges, L, Pérol, D, Escudier, B, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

34. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial

Author

Bracarda, S. Bamias, A. Casper, J. Negrier, S. Sella, A. Staehler, M. Tarazi, J. Felici, A. Rosbrook, B. Jardinaud-Lopez, M. Escudier, B.

Subjects
urologic and male genital diseases
Abstract

Background: Axitinib resulted in significantly longer progression-free survival (PFS) versus sorafenib in patients with metastatic renal-cell carcinoma (mRCC) previously treated with sunitinib in the AXIS trial. We report post hoc analyses evaluating patient subgroups that may benefit more from axitinib in this setting. Patients and Methods: AXIS was an open-label randomized phase 3 trial (NCT00678392) in mRCC patients with disease that failed to respond to one prior systemic therapy. Univariate and multivariate analyses evaluated potential prognostic factors for improved PFS and overall survival (OS) after sunitinib. PFS and OS of axitinib versus sorafenib were assessed within subgroups identified according to these factors. Results: Of 723 patients, 389 received first-line sunitinib; 194 and 195 were randomized to second-line axitinib and sorafenib, respectively. Identified prognostic factors were: nonbulky disease (sum of the longest diameter < 98 mm), favorable/intermediate risk disease (Memorial Sloan Kettering Cancer Center or International Metastatic Renal Cell Carcinoma Database Consortium criteria), and no bone or liver metastases. In patients with all of these prognostic factors (n = 86), significantly longer PFS was observed for axitinib versus sorafenib (hazard ratio = 0.476; 95% confidence interval, 0.263-0.863; 2-sided P =.0126). OS (hazard ratio = 0.902; 95% confidence interval, 0.457-1.780; 2-sided P =.7661) was similar between treatments. Across subgroups, PFS was generally longer in patients treated with axitinib versus sorafenib, and OS was generally similar between the two treatments. Conclusion: In patients with mRCC, axitinib remains a suitable second-line treatment option across multiple subgroups. A relevant reduction in the risk of a PFS event was observed for axitinib compared to sorafenib in selected subgroups of patients. © 2019 The Authors Post hoc analyses of data from patients previously treated with sunitinib in the AXIS trial showed that nonbulky disease is a prognostic factor for second-line treatment. Other factors include favorable/intermediate risk and no bone or liver metastases. Across subgroups, progression-free survival was generally longer with axitinib versus sorafenib. Axitinib remains a suitable second-line treatment for metastatic renal-cell carcinoma. © 2019 The Authors

Published
2019

35. A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)

Author

Bergmann, L., Grimm, M. O., Boleti, E. B., Panic, A., Gruellich, C., Bedke, J., Ahrens, M., Lorch, A., Negrier, S., Ravaud, A., Retz, M., Boegemann, M., Ivanyi, P., Siemer, S., Bathelemy, P., Rottey, S., Maroto, P., Oosting, S., Hartmann, A., Escudier, B., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Published
2019

40. Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights

Author

Stewart, GD, Leibovick, BC, Negrier, S, Figlin, RA, Stewart, Grant [0000-0003-3188-9140], and Apollo - University of Cambridge Repository

Subjects
Sulfonamides, Indazoles, Pyrimidines, Humans, Neoplasm Recurrence, Local, urologic and male genital diseases, neoplasms, Carcinoma, Renal Cell, Nephrectomy, female genital diseases and pregnancy complications, Kidney Neoplasms
Abstract

Improved post-surgical management of the 70% of all renal cell cancer (RCC) patients who present to urological surgeons with initially localised RCC, to prevent subsequent progression, is an area of great need within uro-oncology.

Published
2018
Full Text
View/download PDF

42. NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

Author

Vano, Y., primary, Rioux-Leclercq, N., additional, Dalban, C., additional, Sautès-Fridman, C., additional, Bougoüin, A., additional, Chaput, N., additional, Chouaib, S., additional, Beuselinck, B., additional, Chevreau, C.M., additional, Gross-Goupil, M., additional, Negrier, S., additional, Laguerre, B., additional, Borchiellini, D., additional, Colina-Moreno, I., additional, Fridman, W.H., additional, Chabaud, S., additional, Tantot, F., additional, Barros Monteiro, J., additional, Escudier, B., additional, and Albiges, L., additional

Published
2019
Full Text
View/download PDF

43. Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Author

Albiges, L., primary, Rini, B.I., additional, Haanen, J B A G, additional, Motzer, R.J., additional, Kollmannsberger, C.K., additional, Negrier, S., additional, Nole, F., additional, Bedke, J., additional, Bilen, M.A., additional, Nathan, P., additional, Tomita, Y., additional, Huang, B., additional, Ching, K.A., additional, Chudnovsky, A., additional, Robbins, P.B., additional, di Pietro, A., additional, Thomaidou, D., additional, and Choueiri, T.K., additional

Published
2019
Full Text
View/download PDF

44. ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Author

Butler, M.O., primary, Robert, C., additional, Negrier, S., additional, In, G.K., additional, Walker, J., additional, Krajsova, I., additional, Atkinson, V.G., additional, Hansson, J., additional, Kapiteijn, E., additional, Loquai, C., additional, Shaw, H.M., additional, Cheng, T., additional, Mansard, S., additional, Grob, J.J., additional, Guidoboni, M., additional, Mehta, M., additional, Ascierto, P.A., additional, and Diab, A., additional

Published
2019
Full Text
View/download PDF

45. Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

Author

Lefort, F., primary, Dalban, C., additional, Gross-Goupil, M., additional, Laguerre, B., additional, Barthelemy, P., additional, Sarradin, V., additional, Chanez, B., additional, Negrier, S., additional, Geoffrois, L., additional, Gillon, P., additional, De Vries, M., additional, Ladoire, S., additional, Bolognini, C., additional, Laramas, M., additional, Priou, F., additional, Oudard, S., additional, Chabot, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2019
Full Text
View/download PDF

46. Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients

Author

Saint-Ghislain, M., primary, Geoffrois, L., additional, Gastaud, L., additional, Lesimple, T., additional, Negrier, S., additional, Penel, N., additional, Kurtz, J.-E., additional, Le Corre, Y., additional, Gardrat, S., additional, Barnhill, R., additional, Cassoux, N., additional, Mariani, P., additional, Servois, V., additional, Piperno-Neumann, S., additional, and Rodrigues, M., additional

Published
2019
Full Text
View/download PDF

50. Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

Author

Flippot, R., primary, Dalban, C., additional, Laguerre, B., additional, Borchiellini, D., additional, Gravis, G., additional, Negrier, S., additional, Chevreau, C.M., additional, Joly, F., additional, Geoffrois, L., additional, Ladoire, S., additional, Mahammedi, H., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results